From zero to one: PharmaJet Health-B (2617.HK) launches tianogitinib, marking its commercial debut with a 'world-first' innovation

On August 6, Pharnext’s core product, tienogitinib tablets (Jientai®), received marketing approval for the treatment of adult patients with advanced biliary tract cancer harboring FGFR2 fusions or rearrangements who have previously received systemic therapy and an FGFR inhibitor. $TRANSTHERA-B (02617.HK)$

This is not onlyPharnext’s first product to gain regulatory approval, but also the debut indication for the world’s first-in-class multi-kinase inhibitor.。

From submission of the new drug application to approval, the process took just over seven months. The combination of priority review and breakthrough therapy designation, coupled with this rapid review timeline, strongly underscores regulators’ high confidence in the product’s clinical value.

Amid the current industry cycle, China’s innovative pharmaceutical sector stands at a critical inflection point driven by dual engines of innovation and internationalization. In the first half of the year, 31 domestically developed innovative drugs received approval, and outbound licensing deals totaled nearly USD 100 billion, signaling that the industry as a whole has entered a fast track toward value realization.

This approval of tienogitinib marks Pharnext’s pivotal transition from R&D to commercialization and provides a solid foundation for future value creation.

How substantial is the 'world’s first' designation, supported by late-line clinical data?

The confidence in tienogitinib stems first and foremost from its clinical value.

At the 2026 ASCO Annual Meeting, interim data from the pivotal Phase II clinical trial of tienogitinib (FIRST-08), as of December 27, 2025, were disclosed. All 50 patients with advanced biliary tract cancer have been enrolled; all had previously received at least one line of chemotherapy and one FGFR inhibitor, with 40% having undergone three or more lines of systemic anti-tumor therapy.

Against the backdrop of such an 'extremely difficult-to-treat' patient population, the objective response rate assessed by blinded independent central review reached 28.0%, with a median duration of response of 8.5 months, a disease control rate of 82.0%, and a median overall survival of 20.7 months.

A cross-sectional comparison better highlights the significance of these figures.

In a recent research report, DBS Bank noted that tienogitinib achieved a median overall survival of 20.7 months in a heavily pre-treated third-line patient population—surpassing the average of 18.3 months observed with similar drugs in second-line therapy. In other words, within the late-line, multi-drug-resistant setting where effective interventions are scarce, tienogitinib has already delivered a clear clinical benefit.

Of course, behind these outstanding clinical data lies differentiated molecular design.

Tienogitinib is a multi-targeted inhibitor capable of simultaneously targeting three pathways: FGFR/VEGFR, JAK, and Aurora kinase, each with its own distinct clinical translation rationale:

First, addressing acquired resistance to FGFR inhibition.

Tienogitinib employs a novel chemical scaffold that forms three hydrogen bonds with the hinge region of FGFR, enabling high-affinity binding and effectively circumventing resistance caused by amino acid mutations. Globally, tienogitinib is currently the only approved drug that overcomes this challenge.

Second, targeting lineage plasticity-driven resistance.

Tienogitinib is the world’s only molecule that simultaneously inhibits both FGFR and JAK pathways and has advanced into clinical development. Research shows that activation of these two pathways drives androgen-sensitive prostate cancer cells to transform into a neuroendocrine phenotype, leading to therapeutic resistance. Dual blockade of both pathways can reverse this cellular state transition, restoring cancer cell sensitivity to treatment—a mechanism with clear translational potential in prostate and breast cancers.

Third, exploring the reactivation of immune responses.

Phase II data for tinegotinib in combination with Roche's PD-L1 inhibitor have been read out, showing signs of efficacy even in patients resistant to PD-1/L1 inhibitors. The company has also initiated a Phase II study combining tinegotinib with Akeso Biopharma's bispecific antibody, which is currently enrolling patients to validate the feasibility of synergistic effects from 'targeted therapy plus immunotherapy.'

In cholangiocarcinoma, tinegotinib has a clearly defined positioning—directly addressing the clinical gap where no treatment options exist after FGFR inhibitor resistance. With no similar products approved domestically and few global competitors advancing in this space, this strategic positioning itself carries differentiated commercial value.

Beyond cholangiocarcinoma: the path toward a blockbuster drug

Approval in cholangiocarcinoma is just the starting point.

From sequential expansion into new indications and global clinical advancement to synergistic pipeline integration across the company’s portfolio, PharmaEngine is constructing a multi-layered framework for value realization.

First, simultaneous expansion across multiple indications continues to reinforce tinegotinib’s potential as a blockbuster drug.

In prostate cancer, a Phase II trial of tinegotinib combined with novel endocrine therapy for metastatic castration-resistant prostate cancer that has progressed after prior treatment is actively underway, and the FDA has granted it Fast Track designation. In breast cancer, a Phase II trial combining tinegotinib with fulvestrant for HR+/HER2- recurrent or metastatic breast cancer has dosed its first patient; early data show clear efficacy signals in HR+/HER2- patients who have previously undergone endocrine therapy, CDK4/6 inhibitors, and even chemotherapy. In liver cancer, a Phase II trial evaluating tinegotinib in combination with cadonilimab and ivosidenib as first-line treatment has already been initiated.

These three indications span three distinct solid tumor types—any significant breakthrough in one could substantially elevate tinegotinib’s core valuation.

Second, global clinical development is unlocking international market potential.

The global multicenter registrational Phase III trial of tinegotinib monotherapy in advanced cholangiocarcinoma has completed enrollment across clinical centers in the U.S., Europe, and Asia. The product previously received FDA Orphan Drug Designation and Fast Track status, as well as EMA orphan drug designation for biliary tract cancer. Top-line results from this multinational Phase III trial are expected next year and will support New Drug Applications (NDAs) in multiple regions, including with the FDA and EMA.

Once the path from 'China-first' to 'global footprint' is successfully established, the market ceiling for tienogatinib will no longer be confined to the domestic market alone.

Third, the staggered advancement of its pipeline matrix provides additional support for medium- to long-term value.

TT-00973, a dual AXL/FLT3 inhibitor targeting lung cancer, has advanced to Phase II clinical trials and has entered into a combination therapy collaboration with Allist Pharmaceuticals; TT-01488, a novel non-covalent reversible BTK inhibitor, has completed Phase I trials in relapsed or refractory B-cell malignancies, and its Phase II trial in mantle cell lymphoma—combined with a CD20 monoclonal antibody—has received regulatory approval.

Conclusion

The approval of tienogatinib not only marks PharmAphex’s successful navigation through the most challenging 'zero-to-one' phase typical of innovative biopharma companies, but also signifies a strategic shift in the company’s valuation logic—from pipeline-based estimates to performance-driven validation.

In the near term, commercial ramp-up in cholangiocarcinoma will establish a cash flow foundation; in the medium term, data readouts across multiple indications—including prostate cancer, breast cancer, and liver cancer—as well as global regulatory filings, will continuously expand market perception of this 'first-in-class' molecule; in the long term, the sequential progression of follow-on pipeline candidates will provide ample fuel for sustained growth.

Undeniably, the current moment represents a critical window for re-evaluating PharmAphex’s valuation framework.

31K Views